George P. Scanlon
Known title: DirectorCIK: 0001301099
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Landstar System Analyst Targets Adjusted Amid Supply Chain Focus. Several analysts have revised their price targets for Landstar System, with Truist and JP Morgan cutting their expectations to $175 and $181 respectively, while Wells Fargo keeps an overweight rating at $225. The adjustments come as the company remains a focus for investors watching supply‑chain pressures in the trucking sector. Landstar’s stock is near its 200‑day moving‑average support level of $178.14, adding context to the recent target revisions.
Transaction History
| WEAV | ▲ Buy | Grant | 32,502 | $0 | 6/10/2026 | View on chart |
| LSTR | ▲ Buy | Grant | 825 | $0 | 5/6/2026 | View on chart |
| WEAV | ▲ Buy | Grant | 18,078 | $0 | 5/21/2025 | View on chart |
| LSTR | ▲ Buy | Grant | 1,043 | $0 | 5/19/2025 | View on chart |
| WEAV | ▲ Buy | Grant | 19,383 | $0 | 5/22/2024 | View on chart |
| LSTR | ▲ Buy | Grant | 830 | $0 | 5/8/2024 | View on chart |
| WEAV | ▲ Buy | Grant | 24,356 | $0 | 5/24/2023 | View on chart |
| LSTR | ▲ Buy | Grant | 851 | $0 | 5/11/2023 | View on chart |
| LSTR | ▲ Buy | Grant | 969 | $0 | 5/12/2022 | View on chart |
| WEAV | ▲ Buy | Grant | 59,362 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Weave Clears Antitrust Review, Ranks No. 1 in G2 Report
Weave Communications has cleared the HSR antitrust review, allowing the Francisco Partners deal to proceed with an expected close in Q4 2026. The company also secured the top spot in G2's Fall 2026 Patient Relationship Management Grid Report. These developments highlight regulatory progress and industry recognition for the firm.
Weave Clears Antitrust Review, Ranks No. 1 in G2 Report. Weave Communications has cleared the HSR antitrust review, allowing the Francisco Partners deal to proceed with an expected close in Q4 2026. The company also secured the top spot in G2's Fall 2026 Patient Relationship Management Grid Report. These developments highlight regulatory progress and industry recognition for the firm.